# A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)

> **NCT07732400** · PHASE1,PHASE2 · RECRUITING · sponsor: **Kriya Therapeutics, Inc.** · enrollment: 56 (estimated)

## Conditions studied

- Metabolic Dysfunction-associated Steatohepatitis (MASH)

## Interventions

- **GENETIC:** VV-14303

## Key facts

- **NCT ID:** NCT07732400
- **Lead sponsor:** Kriya Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-30
- **Primary completion:** 2028-07
- **Final completion:** 2029-07
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07732400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07732400, "A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07732400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*